



Original article

The relationship between dietary salt intake and ambulatory blood pressure variability in non-diabetic hypertensive patients

Nihal Ozkayar^{a,*}, Fatih Dede^a, Ihsan Ates^a, Fatma Akyel^a, Tolga Yildirim^b, Bulent Altun^c

^a Ankara Numune Education and Research Hospital, Nephrology Department, Ankara, Turkey

^b Ankara Yildirim Beyazit Education and Research Hospital, Nephrology Department, Ankara, Turkey

^c Hacettepe University Medical Faculty, Nephrology Department, Ankara, Turkey

ARTICLE INFO

Article history:

Received 10 April 2015

Accepted 14 December 2015

Available online 7 July 2016

ABSTRACT

High dietary salt intake was reported to increase blood pressure by numerous studies, but no study has investigated the effect of dietary salt intake on blood pressure variability (BPV). This study aimed to determine if daily salt intake is related to ambulatory BPV. The study included 136 primary hypertensive patients (92 male, 44 female) with a mean age of 50.7 ± 11.1 years. All the patients underwent 24-h ambulatory blood pressure monitoring to determine both the 24-h systolic and 24-h diastolic BPV. 24-h urine sodium was measured. The correlation between BPV and 24-h urinary sodium was investigated. Logarithmic transformation of 24-h urinary sodium [$\log(24\text{-h urinary sodium})$] was positively correlated with the mean 24-h systolic ARV, and nighttime systolic ARV ($r = 0.371$ and $p = 0.001$, $r = 0.329$ and $p = 0.028$, respectively). Similarly, $\log(24\text{-h urinary sodium})$ was positively correlated with mean 24-h diastolic ARV and nighttime diastolic ARV ($r = 0.381$ and $p = 0.001$, $r = 0.320$ and $p = 0.020$ respectively). $\log(24\text{-h urinary sodium})$ was an independent predictor of BPV based on multivariate regression analysis. Dietary salt intake might play a role in the pathogenesis of ambulatory BPV.

© 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Relación entre el consumo de sal y la variabilidad de la presión arterial ambulatoria en pacientes hipertensos no diabéticos

RESUMEN

Palabras clave:

Consumo de sal

Variabilidad de la presión arterial

Hipertensión

En numerosos estudios se ha señalado que el consumo elevado de sal aumenta la presión arterial; no obstante, no se ha investigado el efecto de la ingesta alimenticia de sal sobre la variabilidad de la presión arterial (VPA). El objetivo de este estudio fue determinar si el consumo diario de sal está relacionado con la VPA ambulatoria. En el estudio se incluyeron

* Corresponding author.

E-mail address: nihalozk@gmail.com (N. Ozkayar).

<http://dx.doi.org/10.1016/j.nefro.2015.12.004>

0211-6995/© 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

136 pacientes hipertensos esenciales (92 hombres y 44 mujeres) con una edad media de $50,7 \pm 11,1$ años. Todos los pacientes se sometieron a una monitorización ambulatoria de la presión arterial de 24 h para determinar la VPA sistólica y diastólica de 24 h. Se midió la natriuria de 24 h y se estudió la correlación de la misma con la VPA. La transformación logarítmica de la natriuria de 24 h ($\log [natriuria 24 h]$) se relacionó con certeza con el índice Average Real Variability (ARV) sistólico de 24 h y el ARV sistólico nocturno medios ($r=0,371$ y $p=0,001$, $r=0,329$ y $p=0,028$, respectivamente). De forma parecida, el $\log [natriuria 24 h]$ se relacionó con seguridad con el ARV diastólico de 24 h y el ARV diastólico nocturno medios ($r=0,381$ y $p=0,001$, $r=0,320$ y $p=0,020$, respectivamente). El $\log [natriuria 24 h]$ fue una variable independiente de la VPA, según el análisis de regresión multivariante. Es posible que el consumo de sal intervenga en la patogénesis de la VPA ambulatoria.

© 2016 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Hypertension is a primary risk factor for cardiovascular and cerebrovascular diseases, and renal failure. It is well known that the quantity of dietary salt intake plays a role in the pathogenesis of primary hypertension. Increased sensitivity of blood pressure to excess sodium affects 50% of patients with primary hypertension.^{1,2} Dietary salt intake causes an increase in blood pressure, and is associated with renal and cardiovascular diseases, including left ventricular hypertrophy and microalbuminuria.^{3–5} Spontaneous variation in blood pressure is referred to as blood pressure variability (BPV), and is classified as short-term BPV and long-term BPV.^{6,7} Fluctuation during a 24-h period is referred to as short-term BPV and is based on 24-h ambulatory blood pressure monitoring (ABPM). Variation between successive ABPM measurements is known as average real variability (ARV), which is mathematically calculated.^{8,9} BPV was reported to be associated with hypertension-related target organ damage and cardiovascular mortality, independent of the blood pressure level. BPV, therefore, becomes more important day-by-day.^{10–13} The pathophysiology of BPV is not fully known; however, it was reported that short-term BPV is primarily indicative of the effects of central and reflex autonomic modulation, and is associated with humoral, rheological, emotional, and behavioral factors.^{9,14–18} The relationship between dietary salt intake and ambulatory BPV is not clearly known. Dietary salt intake is known to adversely affect the cardiovascular system, independent of the blood pressure level.^{3,5} Excretion of sodium in 24-h urine is a measurement with proven validity that is commonly used to measure daily salt intake.^{19,20} The aim of the present study was to determine if the quantity of daily salt intake is associated with ambulatory BPV.

Materials and methods

Study population

This study was performed at Ankara Numune Education and Research Hospital, Nephrology and Internal Medicine Clinic, Ankara, Turkey, and included 136 patients that

presented between April 2013 and July 2013, and were diagnosed as primary hypertension. Exclusion criteria were diabetes mellitus, secondary hypertension, pregnancy, body mass index (BMI) $> 30 \text{ kg/m}^2$, malignancy, rheumatic diseases, acute/chronic infection, liver disease, thyroid gland disease, adrenal insufficiency, syndrome of inappropriate antidiuretic hormone secretion, nephritis with salt loss, renal tubular acidosis, and a glomerular filtration rate $< 70 \text{ mL/min/1.73 m}^2$ and diuretic use. Duration of hypertension [years] was calculated based on patient self-reports of the date they were first diagnosed as hypertension to the date of inclusion in the study. The study was conducted in accordance with the Declaration of Helsinki and the study protocol was approved by the Ankara Numune Education and Research Hospital Ethics Committee. All the patients provided written informed consent to participate in the study.

Laboratory procedures

Blood samples were collected at 08.00–10.00, following overnight fasting. Laboratory evaluations included whole blood count, fasting blood glucose, urea, creatinine, sodium, potassium, total protein, and albumin. The GFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation: $\text{GFR} = 141 \times \min(\text{Scr}/\kappa, 1)^\alpha \times \max(\text{Scr}/\kappa, 1)^{-1.209} \times 0.993^{\text{age}} \times 1.018$ [if female] $\times 1.159$.²¹

24-h urine collection

Patients were asked to collect 24-h urine; they were instructed not to save the urine from their first urination the morning they started to collect their urine, and to urinate into a collection container every time thereafter, including the first urination the following morning, and then to bring all collected urine to the laboratory. Patients were told not to make any changes to their daily dietary salt intake and to follow their normal diet during the time of urine collection. Urine sodium was measured in the patients' 24-h urine via the enzymatic colorimetric method using a Hitachi Modular P800 (Roche Diagnostic Corp. Indiana, USA) autoanalyzer. For each individual the 24-h sodium excretion value (mmol/d) was calculated

as the concentration of sodium in the urine (mmol/L) × urinary volume (L/d).

Ambulatory blood pressure monitoring and its variability

A WatchBP 03 device (Microlife WatchBP AG, Switzerland) was attached to all patients for 24-h ABPM the morning they began to collect 24-h urine. The ABPM device was set to take measurements every 20 min between 08.00 and 23.00 (daytime), and every 30 min between 23.00 and 08.00 (nighttime). Patients were told to perform their normal daily activities, but not to bend their arm during measurements. These measurements provided 24-h systolic and 24-h diastolic blood pressure values. The method was considered reliable if >70% of measurements were valid. BPV was mathematically calculated as the blood pressure values from 24-h ABPM and the ARV index,

$$\text{using the following formula: } \text{ARV} = \frac{1}{N-1} \sum_{k=1}^{N-1} |BP_{k+1} - BP_k| \text{ where}$$

N is the number of valid blood pressure measurements, and BP_{k+1} and BP_k represent 2 successive blood pressure measurements. The rationale for selecting the ARV index for BPV calculation was based on an earlier study that reported the ARV index was a more reliable index for establishing the prognostic significance of BPV.⁸

Statistical analysis

Statistical analysis was performed using SPSS v.20.0 for Windows (SPSS, Inc., Chicago, USA) and STATA/SE v.12.0 for Windows (StataCorp LP, Texas, USA). The Kolmogorov-Smirnov test was used to determine the normality of the distribution of data. Continuous variables with normal distribution are expressed as mean \pm SD, and continuous variables without normal distribution are expressed as median (range). Categorical variables are presented as number and percentage. If there was substantial skewing of urinary sodium values, logarithmic transformation (Log) was applied to subordinate the skewness of these values. Continuous variables were compared via the independent samples t-test or the Mann-Whitney U test, as appropriate. Categorical variables were compared using the chi-square test. Relationships between numeric parameters were analyzed via Pearson's and Spearman's correlation analysis. Stepwise multiple linear regression analysis was performed to identify independent determinants of 24-h systolic ARV, 24-h diastolic ARV, nighttime systolic ARV, and nighttime diastolic ARV. The level of statistical significance was set at $p < 0.05$.

Results

The study included 136 patients (92 male and 44 female). Mean age of the patients was 50.78 ± 11.1 years. Patient demographic characteristics, and laboratory and ABPM findings are shown in Table 1. BPV and mean 24-h blood pressure levels, and the correlations between other parameters are shown in Table 2.

Systolic blood pressure level was positively correlated with log(24-h urinary sodium) ($r = 0.294$, $p = 0.024$), BMI ($r = 0.183$, $p = 0.033$), creatinine ($r = 0.226$, $p = 0.008$), 24-h systolic ARV

Table 1 – Demographic, laboratory characteristics and ABPM results of all patients.

Variables	All populations (n = 136)
Age (years)	50.78 (11.1)
Gender (n, %)	
Male	92 (67.6)
Female	44 (32.4)
BMI (kg/m^2)	29.16 (4.5)
Duration of HT (years)	3 (1–20)
Anti-hypertensive drug class (n, %)	
RAS blocker	66 (48.5)
Beta blocker	24 (17.6)
Calcium channel blocker	72 (52.9)
GFR ($\text{mL}/\text{min}/1.73 \text{ m}^2$)	97.57 (10.2)
Serum sodium	141.11 (2.1)
Glucose (mg/dL)	89.94 (5.7)
Albumin (g/dL)	46.28 (2.8)
Creatinine (mg/dL)	0.79 (0.1)
Triglyceride (mg/dL)	157 (61–735)
LDL (mg/dL)	122.52 (35.5)
24-h urine sodium (mmol/d)	152 (21–387)
24-h urine protein (mg/d)	89.63 (6–1949)
24-h systolic ARV	12.33 (3.4)
24-h diastolic ARV	9.77 (2.6)
Nighttime systolic ARV	11.16 (3.9)
Nighttime diastolic ARV	8.78 (2.9)
24-h SBP (mmHg)	122.48 (13.2)
24-h DBP (mmHg)	76.29 (8.50)

Parameters were expressed as mean \pm SD or median. Abbreviations: ARV, average real variability; BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; LDL, low density lipoprotein; SBP, systolic blood pressure; RAS, renin angiotensin system.

($r = 0.317$, $p = 0.001$), and nighttime systolic ARV ($r = 0.375$, $p = 0.001$).

Diastolic blood pressure level was positively correlated with log(24-h urinary sodium) ($r = 0.293$, $p = 0.025$), BMI ($r = 0.192$, $p = 0.030$), creatinine ($r = 0.201$, $p = 0.019$), 24-h diastolic ARV ($r = 0.333$, $p = 0.006$), and nighttime diastolic ARV ($r = 0.384$, $p = 0.001$).

Mean 24-h systolic ARV, mean nighttime systolic ARV, and mean systolic blood pressure did not significantly differ according gender. Mean 24-h systolic ARV, nighttime systolic ARV, and mean systolic blood pressure did not significantly differ between the patients that did and did not use anti-hypertensive drug.

Mean 24-h diastolic ARV, mean nighttime diastolic ARV blood pressure, and diastolic blood pressure did not significantly differ by gender. Mean 24-h diastolic ARV, mean nighttime diastolic ARV blood pressure, and diastolic blood pressure did not significantly differ between patients that did and did not use anti-hypertensive medication.

In evaluation of all patients for types of antihypertensive drugs used, means of blood pressure levels and ARVs for patients received renin angiotensin system blocker, calcium channel blocker, and beta blocker were similar ($p > 0.05$).

Log(24-h urinary sodium) did not significantly differ according to gender, or anti-hypertensive drug class, and was not associated with other laboratory findings.

Table 2 – The parameters which correlated with diastolic and systolic average real variability.

Variables	24-h diastolic ARV		Night diastolic ARV		24-h systolic ARV		Night systolic ARV	
	r	p	r	p	r	p	r	p
Age	0.092	0.287	0.036	0.675	0.046	0.591	0.034	0.697
BMI	0.222	0.009*	0.114	0.188	0.156	0.071	0.135	0.117
Duration of HT	-0.037	0.677	-0.110	0.220	0.091	0.310	0.014	0.876
24-h SBP	0.116	0.177	0.159	0.065	0.317	0.001*	0.375	0.011*
24-h DBP	0.333	0.006*	0.384	0.001*	0.115	0.136	0.117	0.168
Log(24-h urine sodium)	0.381	0.001*	0.320	0.020*	0.371	0.001*	0.329	0.028*
Log(24-h urine sodium) ^a	0.338	0.004*	0.315	0.031*	0.342	0.002*	0.323	0.025*
24-h urine protein	-0.095	0.270	0.074	0.390	0.083	0.335	0.076	0.377
Glucose	0.048	0.661	0.175	0.110	0.074	0.501	0.114	0.299
GFR	0.164	0.066	-0.029	0.740	0.109	0.064	0.008	0.925
Albumin	-0.103	0.235	-0.051	0.557	-0.010	0.906	-0.057	0.510
Serum Sodium	0.027	0.754	0.076	0.383	0.031	0.724	0.023	0.787
Creatinine	0.238	0.005*	0.225	0.009*	0.297	0.001*	0.232	0.006*
Triglyceride	-0.002	0.984	0.170	0.072	0.002	0.980	0.055	0.532
LDL	-0.068	0.438	-0.018	0.838	0.047	0.593	0.028	0.748

Abbreviations: ARV, average real variability; BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; LDL, low-density lipoprotein; SBP, systolic blood pressure.

^a Adjustment for 24-h SBP and 24-h DBP.

* p<0.05 is considered significant for statistical analyses.

The positive correlation between log(24-h urinary sodium) and 24-h systolic ARV, and nighttime systolic ARV, 24-h diastolic ARV, nighttime diastolic ARV persisted when the effect of systolic and diastolic blood pressure levels were adjusted for.

Log(24-h urinary sodium) was positively correlated with mean 24-h systolic ARV and nighttime systolic ARV ($r=0.371$ and $p=0.001$, $r=0.329$ and $p=0.028$, respectively) (Figs. 1 and 2). Similarly, log(24-h urinary sodium) was positively correlated with mean 24-h diastolic ARV and nighttime diastolic ARV ($r=0.381$ and $p=0.001$, $r=0.320$ and $p=0.020$, respectively) (Figs. 3 and 4). The positive correlation also persisted when systolic and diastolic blood pressures, gender and BMI were adjusted for.

Age, male gender, BMI, duration of hypertension, and anti-hypertensive drug class, systolic blood pressure, diastolic blood pressure, log(24-h urine sodium), 24-h urine

microalbuminuria, 24-h urine protein excretion, glucose, GFR, albumin, serum sodium, creatinine, triglyceride, and LDL levels were included in a stepwise regression model. Log(24-h urine sodium) was observed to be an independent predictor of BPV based on multivariate regression analysis (Table 3).

Discussion

In the present study there was a positive correlation between the 24-h urine sodium level and 24-h systolic and 24-h diastolic BPV derived from ABPM in patients diagnosed as primary hypertension. In addition, there was a positive correlation between 24-h urine sodium, and mean 24-h systolic and 24-h diastolic blood pressure levels based on ABPM. The effect of the quantity of dietary salt intake on blood pressure has been investigated in numerous epidemiological screening studies, clinical studies, and experimental animal trials^{1,22–24}.




Fig. 1 – The correlation with 24-h systolic ARV and log(24-h urinary sodium).




Fig. 2 – The correlation with nighttime systolic ARV and log(24-h urinary sodium).




Fig. 3 – The correlation with 24-h diastolic ARV and log(24-h urinary sodium).




Fig. 4 – The correlation with nighttime diastolic ARV and log(24-h urinary sodium).

however, to the best of our knowledge the present study is the first to investigate the relationship between the quantity of daily salt intake and ambulatory BPV in hypertensive patients.

Dietary salt intake is a rectifiable environmental factor associated with the pathogenesis of primary hypertension. Conclusive evidence shows that high-level dietary salt intake is closely associated with high blood pressure and the development of hypertension-related target organ damage^{20,24,25}; however, many studies report that high dietary sodium intake negatively affects the cardiovascular and cerebrovascular systems, independent of elevated blood pressure.²⁶ It has been suggested that high dietary salt intake adversely affects remodeling in central and peripheral arteries, and increases arterial stiffness, independent of increasing blood pressure.^{27,28} A study that included normotensive participants reported that sodium excretion in 24-h urine was positively

correlated with CIMT, independent of blood pressure, which was suggested to be because a high-salt diet could result in a flow-related increase in shear stress and induce compensatory arterial wall thickening without increasing blood pressure.

Endothelium-dependent vascular function and arterial walls are negatively affected by salt load. These effects of high salt intake on target organs are linked to the fibrogenic activity of transforming growth factor (TGF)-beta1, as TGF-beta1 production has been shown to increase during high salt intake.²⁹ High salt intake also stimulates vascular growth by increasing the response to angiotensin 2, vasopressin, and several growth factors. In general, BPV is considered to occur due to interaction between environmental, behavioral, neural (central or reflex), humoral (insulin, angiotensin II, bradykinin, endothelin-1, and nitric oxide), and myogenic factors^{14,15,30-32}; however, the precise factors responsible for

Table 3 – Independent predictors for average real variability by multivariate regression analysis.

Characteristic	B ± SE	95 C.I.	p value	
24-h diastolic ARV				$R^2 = 0.219, p < 0.001$
24-h DBP	0.043 (0.015)	0.010	0.091	0.009*
Log(24-h urine sodium)	2.601 (0.852)	0.916	4.285	0.003*
Creatinine	3.435 (1.458)	0.752	6.519	0.014*
24-h systolic ARV				$R^2 = 0.237, p < 0.001$
24-h SBP	0.054 (0.021)	0.012	0.096	0.001*
Log(24-h urine sodium)	3.390 (1.094)	1.226	5.554	0.010*
Creatinine	5.072 (1.867)	1.379	8.764	0.007*
Nighttime diastolic ARV				$R^2 = 0.225, p < 0.001$
24-h DBP	0.048 (0.019)	0.029	0.101	0.003*
Log(24-h urine sodium)	2.431 (0.821)	0.788	3.450	0.038*
Creatinine	3.626 (1.733)	1.119	7.053	0.028*
Nighttime systolic ARV				$R^2 = 0.229, p < 0.001$
24-h SBP	0.059 (0.025)	0.010	0.109	0.021*
Log(24-h urine sodium)	2.462 (0.713)	1.084	5.056	0.033*
Creatinine	4.448 (1.938)	1.221	8.875	0.014*

Abbreviations: ARV, average real variability; DBP, diastolic blood pressure; SBP, systolic blood pressure.

* $p < 0.05$ is considered significant for statistical analyses.

BPV remain unclear. Sympathovagal reflex has been shown to play a role in BPV in healthy individuals.³² Additionally, among the proposed vascular mechanisms of BPV is alteration in arterial distensibility.³³ BPV was also associated with changes in arterial blood vessel walls, including a decrease in arterial compliance and an increase in arterial stiffness, in healthy young males and patients with cardiovascular disease.^{17,31}

In the present study the observed correlation between 24-h urine sodium and ambulatory BPV might have been due to the effect of salt on the arterial system. Research has suggested that salt-sensitive hypertension was associated with the autonomic nervous system, and that the sympathetic nervous system was hyperactivated and the parasympathetic system was inhibited in such patients.³⁴ These findings are consistent with experimental animal studies in which the blood pressure in rats decreased following sympathetic current blockade or severing of sympathetic nerves.^{35,36}

The central nervous system is suggested to play an important role in producing and maintaining high blood pressure in individuals with salt-sensitive hypertension. Central and reflex autonomic modulation is known to play a role in the pathophysiology of BPV. Rat studies showed that BPV was associated with reduced cardiac baroreflex.³⁷ A study on the association between BPV and daily salt intake in normotensive individuals reported that dietary salt intake negatively affected centrally mediated cardiovascular reflex, resulting in an increase in BPV. Several studies reported that BPV is regulated by sympathovagal balance and arterial distensibility.^{2–4} Based on these findings, several mechanisms might contribute to increased BPV in hypertensive patients with a high-salt diet. Increased BPV might be partially due to diminished baroreflex function associated with increased stiffness and reduced compliance in large elastic arteries.^{26,27} Dietary salt intake might directly regulate or activate sympathetic nerve activity, and might indirectly modulate BPV; however, the cross-sectional design of the present study limits the ability to conclude that there is a causal relationship between salt intake and BPV.

In conclusion, the major finding of the present study is that primary hypertensive patients with high dietary salt intake had high BPV. The relationship between high salt intake and an increase in BPV was independent of the blood pressure level. These findings suggest that under similar blood pressure levels high salt intake may be associated with increased BPV. Additional larger-scale prospective studies are needed to further clarify the relationship between salt intake, BPV, and cardiovascular disease. Patients with a high-salt diet could be at increased risk for cardiovascular disease due to the adverse effects of BPV on the cardiovascular system. High dietary salt intake in hypertensive patients can result in elevated blood pressure and might contribute to cardiovascular morbidity due to an increase in blood pressure.

Financial disclosure

None to declare.

Conflicts of interest

The authors report no conflicts of interest.

Acknowledgement

None.

REFERENCES

- Elliott P, Stamler J, Nichols R, Dyer AR, Stamler R, Kesteloot H, et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. *BMJ*. 1996;312:1249–53.
- Weinberger MH. Salt sensitivity of blood pressure in humans. *Hypertension*. 1996;27:481–90.
- Tuomilehto J, Jousilahti P, Rastenyte D, Moltchanov V, Tanskanen A, Pietinen P, et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. *Lancet*. 2001;357:848–51.
- Messerli FH, Schmieder RE, Salt Weir MR. A perpetrator of hypertensive target organ disease. *Arch Intern Med*. 1997;157:2449–52.
- Verhave JC, Hillege HL, Burgerhof JG, Janssen WM, Gansevoort RT, Navis GJ, et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. *J Intern Med*. 2004;256:324–30.
- Lewis O. Stephen Hales and the measurement of blood pressure. *J Hum Hypertens*. 1994;8:865–71.
- Parati G, Ochoa JE, Lombardi C, Salvi P, Bilo G. Assessment and interpretation of blood pressure variability in a clinical setting. *Blood Press*. 2013;22:345–54.
- Mena L, Pintos S, Queipo NV, Aizpurua JA, Maestre G, Sulbaran T. A reliable index for the prognostic significance of blood pressure variability. *J Hypertens*. 2005;23:505–11.
- Parati G, Saul JP, Di Renzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. *Hypertension*. 1995;25:1276–86.
- Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G, et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). *Hypertension*. 2002;39:710–4.
- Ozkayar N, Altun B, Yildirim T, Yilmaz R, Dede F, Arik G, et al. Blood pressure measurements, blood pressure variability and endothelial function in renal transplant recipients. *Clin Exp Hypertens*. 2014;36:392–7.
- Mancia G, Parati G, Hennig M, Flatau B, Omponi S, Glavina F, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). *J Hypertens*. 2001;19:1981–9.
- Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. *J Hypertens*. 1987;5:939–48.
- Conway J, Boon N, Davies C, Jones JV, Sleight P. Neural and humoral mechanisms involved in blood pressure variability. *J Hypertens*. 1984;2:203–8.
- Mancia G, Parati G, Pomidossi G, Casadei R, Di Renzo M, Zanchetti A. Arterial baroreflexes and blood pressure and heart rate variabilities in humans. *Hypertension*. 1986;8:147–53.
- Parati G, Faini A, Valentini M. Blood pressure variability: its measurement and significance in hypertension. *Curr Hypertens Rep*. 2006;8:199–204.
- Schillaci G, Bilo G, Pucci G, Laurent S, Macquin-Mavier I, Boutouyrie P, et al. Relationship between short-term blood

- pressure variability and large-artery stiffness in human hypertension: findings from 2 large databases. *Hypertension*. 2012;60:369–77.
- 18. Floras JS. Blood pressure variability: a novel and important risk factor. *Can J Cardiol*. 2013;29:557–63.
 - 19. Luft FC, Fineberg NS, Sloan RS. Estimating dietary sodium intake in individuals receiving a randomly fluctuating intake. *Hypertension*. 1982;4:805–8.
 - 20. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. *BMJ*. 1988;297:319–28.
 - 21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): a new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150:604–12.
 - 22. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. *Am J Clin Nutr*. 1997;65:643S–51S.
 - 23. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med*. 2001;344:3–10.
 - 24. Denton D, Weisinger R, Mundy NI, Wickings EJ, Dixson A, Moisson P, et al. The effect of increased salt intake on blood pressure of chimpanzees. *Nat Med*. 1995;1:1009–16.
 - 25. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. *N Engl J Med*. 1997;336:1117–24.
 - 26. Ekinci EI, Clarke S, Thomas MC, Moran JL, Cheong K, MacIsaac RJ, et al. Dietary salt intake and mortality in patients with type 2 diabetes. *Diabetes Care*. 2011;34:703–9.
 - 27. Stocker SD, Madden CJ, Sved AF. Excess dietary salt intake alters the excitability of central sympathetic networks. *Physiol Behav*. 2010;100:519–24.
 - 28. Liu Z, Peng J, Lu F, Zhao Y, Wang S, Sun S, et al. Salt loading and potassium supplementation: effects on ambulatory arterial stiffness index and endothelin-1 levels in normotensive and mild hypertensive patients. *J Clin Hypertens (Greenwich)*. 2013;15:485–96.
 - 29. Ying WZ, Sanders PW. Dietary salt modulates renal production of transforming growth factor-beta in rats. *Am J Physiol*. 1998;274:F635–41.
 - 30. Siche JP, Herpin D, Asmar RG, Poncelet P, Chamontin B, Comparat V, et al. Non-invasive ambulatory blood pressure variability and cardiac baroreflex sensitivity. *J Hypertens*. 1995;13:1654–9.
 - 31. Kotsis V, Stabouli S, Karafillis I, Papakatsika S, Rizos Z, Miyakis S, et al. Arterial stiffness and 24 h ambulatory blood pressure monitoring in young healthy volunteers: the early vascular ageing Aristotle University Thessaloniki Study (EVA-ARIS Study). *Atherosclerosis*. 2011;219:194–9.
 - 32. Laitinen T, Hartikainen J, Niskanen L, Geelen G, Lansimies E. Sympathovagal balance is major determinant of short-term blood pressure variability in healthy subjects. *Am J Physiol*. 1999;276:H1245–52.
 - 33. Dabire H, Lacolley P, Chaouche-Teyara K, Fournier B, Safar ME. Relationship between arterial distensibility and low-frequency power spectrum of blood pressure in spontaneously hypertensive rats. *J Cardiovasc Pharmacol*. 2002;39:98–106.
 - 34. Mancia G, Grassi G. The central sympathetic nervous system in hypertension. *Handb Clin Neurol*. 2013;117:329–35.
 - 35. Irigoyen MC, Krieger EM. Baroreflex control of sympathetic activity in experimental hypertension. *Braz J Med Biol Res*. 1998;31:1213–20.
 - 36. Alexander N, Velasquez MT, Decuir M, Maronde RF. Indices of sympathetic activity in the sinoaortic-denervated hypertensive rat. *Am J Physiol*. 1980;238:H521–6.
 - 37. Wang DS, Xie HH, Shen FM, Cai GJ, Su DF. Blood pressure variability, cardiac baroreflex sensitivity and organ damage in experimentally hypertensive rats. *Clin Exp Pharmacol Physiol*. 2005;32:545–52.